Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer

Published:2024-03 Issue: Volume:101 Page:117609
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Liu Jiuyu,Huang Jingxuan^ORCID,Wang Kang,Li Yuan,Li Chunting,Zhu Yanli,He Xinzi,Zhang Yating,Zhao Yanfang,Hu Changliang,Xi Zhiguo,Tong Minghui,Li Zhiwei,Gong Ping,Hou Yunlei^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference29 articles.

1. Mechanisms of drug resistance in kinases;Barouch-Bentov;Exp Opin Invest Drugs.,2011

2. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies;Lovly;Clin. Canc. Res.,2014

3. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm;Fu;Eur J Med Chem,2017

4. Plk1 inhibition enhances the effificacy of BET epigenetic reader blockade in castrationresistant prostate cancer;Mao;Mol. Canc. Therapeut.,2018

5. Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy;Stratikopoulos;Canc. Cell.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP